Figure legends
Figure 1. Patient’s medical history including timeline of events and course of illness and treatments. CD19-20, Cluster of Differentiation 19 and 20; MG, Myasthenia Gravis.
Figure 2. Patient’s medical history including myasthenic crises (red circles), eculizumab and ravulizumab treatment regimens, and related patient- and physician-reported outcome measure scores assessing myasthenia gravis symptoms and severity, quality of life, and activities of daily living. MG-ADL, Myasthenia Gravis Activities of Daily Living; MG-QoL15, Myasthenia Gravis Quality of Life 15-item questionnaire; QMG, Quantitative Myasthenia Gravis.
Key words: myasthenia gravis, generalized myasthenia gravis, eculizumab, ravulizumab, case report, real-world evidence
Author contributions: Conceptualization, formal analysis and investigation, and writing (original draft preparation, review, and editing) was done by Stefan Quasthoff.
Acknowledgements: The author would like to thank the patient for their willingness to have their case reported. Editorial assistance and writing support were provided by Nicole Bezuidenhout, PhD of TFS HealthScience.
Funding information: This research has received no external funding. Writing assistance was funded by Alexion Pharmaceuticals.
Conflict of interest statement : Stefan Quasthoff has received funding for research and consulting from Argenx, Alexion, Astra Zeneca, Biogen, CLS Behring, and Kedrion.
Data availability statement: The data supporting the findings of this case report are available from the corresponding author upon reasonable request.
Ethics approval statement: None
Informed consent: Written informed consent was obtained from the patient in line with the journal’s patient consent policy.
ORCID ID: Stefan Quasthoff https://orcid.org/0000-0003-4183-8320